Radicava (edaravone, Mitsubishi Tanabe Pharma America), an intravenous therapy indicated for all adult patients diagnosed with amyotrophic lateral sclerosis (ALS), is now available for treatment in the United States. The first FDA-approved ALS treatment option in more than 20 years, Radicava has been shown to slow the decline in the loss of physical function in ALS patients by 33 percent. Administered in 28-day cycles through an IV, patients can undergo treatment at an ALS center, physician’s office, free-standing infusion center, hospital outpatient department, or through a home infusion provider, depending on their health plan and physician’s determination. Physicians can initiate patient access to the product and the benefits investigation process through the Searchlight Support hub, which provides assistance for people who are prescribed Radicava.Next Story
Recently Approved ALS Treatment Radicava Now Available
Tuesday, August 08, 2017
You must be logged in to leave a comment.